CJCydney N. Johnson

Cydney N. Johnson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cydney N. Johnson has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mucin promotes pneumococcal colonization via autolysis suppression and tryptophan-mediated immune modulation

    by Cydney N. Johnson, Matthew W. Frank, Yuri Laguna-Terai, William MacCain, Tyler S. Simmons, Svetlana Zamakhaeva, Natalia Korotkova, Carol Aherne, Elaine Tuomanen, Christopher M. Evans, et al.

    Streptococcus pneumoniae is a leading human respiratory pathogen, yet its success depends not on disease but on its ability to persist as an asymptomatic colonizer of the nasopharynx. The nasopharyngeal mucosa is lined with mucus, whose heavily O-glycosylated mucin proteins are the most abundant macromolecules in the pneumococcal natural niche. While mucus is canonically viewed as a host defense barrier, we found that mucin actively reprograms pneumococcal physiology to promote colonization through two distinct mechanisms. First, mucin suppresses pneumococcal autolysis by specifically inhibiting the enzymatic activity of the major autolysin LytA, prolonging bacterial survival and restricting release of the cholesterol-dependent cytotoxin pneumolysin, thereby reducing host cell damage. Second, mucin induces de novo biosynthesis and extracellular release of tryptophan, an essential amino acid that humans cannot synthesize and that serves as a substrate for host immunomodulatory pathways. Tryptophan biosynthesis was critical for pneumococcal survival against macrophage killing, and its disruption abolished both colonization and invasive disease. Transcriptomic analysis revealed that tryptophan biosynthesis enables the pneumococcus to survive a bactericidal macrophage state while preventing macrophage transition to proliferative tissue repair. Together, these findings reveal that mucin is not merely a barrier but an active signal that reprograms the pneumococcus toward a persistent, host-tolerant state, identifying a distinctive repertoire of colonization mechanisms that allow a virulent respiratory pathogen to sustain long-term asymptomatic carriage in its human reservoir.

  • Open Access

    Mechanisms of 10-hydroxyoctadecanoic acid resistance in Streptococcus pneumoniae

    by Cydney N. Johnson, Matthew W. Frank, Chrispin Chaguza, Brendan T. Morrow, Qidong Jia, Christopher D. Radka, Jason W. Rosch

    Profiles of human nasal colonization consistently demonstrate that Staphylococcus aureus and Streptococcus pneumoniae can co-exist in the nasopharynx. Several studies have demonstrated the antagonist relationship between the two organisms via several molecular mechanisms, including competition for nutrients as well as via direct killing by hydrogen peroxide. During nasal colonization, the pneumococcus is in direct contact with the fatty acid h 18:0, which is released into the extracellular environment by S. aureus . We report that h 18:0 is specifically toxic to the pneumococcus among the pathogenic streptococci, providing a unique mechanism for interspecies competition during colonization. Exposure of cells to h 18:0 revealed that S. pneumoniae could rapidly adapt to and overcome the observed toxicity. Whole-genome analysis revealed the mechanism underlying this resistance being linked to a truncation of a glycosyltransferase in the capsule biosynthesis locus and a genomic inversion in the phase variation locus, leading to altered cell surface charge and membrane lipid composition. These physiological differences in the resistant isolates may aid in repelling toxic, charged fatty acids such as h 18:0 from the cell membrane. IMPORTANCE: The pneumococcus and S. aureus are two of the most well-characterized residents of the human nasopharynx; yet much remains unknown regarding how the two bacteria interact. Here, we describe the potential of S. aureus -produced h 18:0, whose function and biological impact are still being described, to act as an interspecies competition molecule against S. pneumoniae , and how the pneumococcus can adapt to overcome its toxicity.

  • Open Access

    An enterococcal phage protein inhibits type IV restriction enzymes involved in antiphage defense

    by Nathan P. Bullen, Cydney N. Johnson, Shelby E. Andersen, Garima Arya, Sonia R. Marotta, Yan-Jiun Lee, Peter R. Weigele, John C. Whitney, Breck A. Duerkop

    The prevalence of multidrug resistant (MDR) bacterial infections continues to rise as the development of antibiotics needed to combat these infections remains stagnant. MDR enterococci are a major contributor to this crisis. A potential therapeutic approach for combating MDR enterococci is bacteriophage (phage) therapy, which uses lytic viruses to infect and kill pathogenic bacteria. While phages that lyse some strains of MDR enterococci have been identified, other strains display high levels of resistance and the mechanisms underlying this resistance are poorly defined. Here, we use a CRISPR interference (CRISPRi) screen to identify a genetic locus found on a mobilizable plasmid from Enterococcus faecalis involved in phage resistance. This locus encodes a putative serine recombinase followed by a Type IV restriction enzyme (TIV-RE) that we show restricts the replication of phage phi47 in vancomycin-resistant E. faecalis. We further find that phi47 evolves to overcome restriction by acquiring a missense mutation in a TIV-RE inhibitor protein. We show that this inhibitor, termed type IV restriction inhibiting factor A (tifA), binds and inactivates diverse TIV-REs. Overall, our findings advance our understanding of phage defense in drug-resistant E. faecalis and provide mechanistic insight into how phages evolve to overcome antiphage defense systems.


  • Open Access

    A 44-Nucleotide Region in the Chikungunya Virus 3′ UTR Dictates Viral Fitness in Disparate Host Cells

    by Stephanie E. Ander, Kathryn S. Carpentier, Wes Sanders, Cormac J. Lucas, Austin J. Jolly, Cydney N. Johnson, David W. Hawman, Mark T. Heise, Nathaniel J. Moorman, Thomas E. Morrison

    We previously reported that deletion of a 44-nucleotide element in the 3′ untranslated region (UTR) of the Chikungunya virus (CHIKV) genome enhances the virulence of CHIKV infection in mice. Here, we find that while this 44-nucleotide deletion enhances CHIKV fitness in murine embryonic fibroblasts in a manner independent of the type I interferon response, the same mutation decreases viral fitness in C6/36 mosquito cells. Further, the fitness advantage conferred by the UTR deletion in mammalian cells is maintained in vivo in a mouse model of CHIKV dissemination. Finally, SHAPE-MaP analysis of the CHIKV 3′ UTR revealed this 44-nucleotide element forms a distinctive two-stem-loop structure that is ablated in the mutant 3′ UTR without altering additional 3′ UTR RNA secondary structures.


  • Open Access

    Genetically distant bacteriophages elicit unique genomic changes in Enterococcus faecalis

    by Cydney N. Johnson, Dennise Palacios Araya, Viviane Schink, Moutusee Islam, Mihnea R. Mangalea, Emily K. Decurtis, Tuong-Vi Cindy Ngo, Kelli L. Palmer, Breck A. Duerkop

    The human microbiota harbors diverse bacterial and bacteriophage (phage) communities. Bacteria evolve to overcome phage infection, thereby driving phage evolution to counter bacterial resistance. Understanding how phages promote genetic alterations in medically relevant bacteria is important as phages continue to become established biologics for the treatment of multidrug-resistant (MDR) bacterial infections. Before phages are used as standalone or combination antibacterial therapies, we must obtain a deep understanding of the molecular mechanisms of phage infection and how host bacteria alter their genomes to become resistant. We performed coevolution experiments using a single Enterococcus faecalis strain and two distantly related phages, to determine how phage pressure impacts the evolution of the E. faecalis genome. Whole genome sequencing revealed mutations previously demonstrated to be essential for phage infection. We also identified mutations in several genes previously unreported to be associated with phage infection in E. faecalis . Intriguingly, there was only one shared mutation in the E. faecalis genome in response to each of the two phages tested, demonstrating that infection by genetically distinct phages results in different host responses. This study shows that infection of the same host by disparate phages leads to evolutionary trajectories that result in distinct genetic changes. This implies that bacteria respond to phage pressure through host responses that are tailored to specific phages. This work serves as the basis for the study of E. faecalis genome evolution during phage infection and will inform the design of future therapeutics, such as phage cocktails, intended to target MDR E. faecalis . IMPORTANCE: Studies characterizing the genome evolution of bacterial pathogens following phage selective pressure are lacking. Phage therapy is experiencing a rebirth in Western medicine. Such studies are critical for understanding how bacteria subvert phage infection and how phages evolve to counter such mutations. This study utilizes comparative genomic analyses to demonstrate how a pathogenic strain of Enterococcus faecalis responds to infection by two genetically distant phages. We show that genetic alterations in the E. faecalis genome accumulate in a manner that is specific to the infecting phage with little to no overlap in shared fixed mutations. This suggests that bacterial genome evolution in response to phage infection is uniquely tied to phage genotype, and sets a precedence for investigations into how phages drive bacterial genome evolution relevant to phage therapeutic applications.

  • Open Access

    Dyeing to connect

    by Cydney N. Johnson, Breck A. Duerkop

    Culture-independent methods capable of connecting bacteriophages (phages) to their target host bacteria will help define the roles of phages in host-associated microbiotas. A recent study used fluorescently dyed intestinal phages to identify novel phage–bacterial interactions from the human intestine.


  • Bacteriophage Resistance Alters Antibiotic-Mediated Intestinal Expansion of Enterococci

    by Anushila Chatterjee, Cydney N Johnson, Phat Luong, Karthik Hullahalli, Sara W McBride, Alyxandria M Schubert, Kelli L Palmer, Paul E Carlson, Breck A Duerkop

    Enterococcus faecalis is a human intestinal pathobiont with intrinsic and acquired resistance to many antibiotics, including vancomycin. Nature provides a diverse and virtually untapped repertoire of bacterial viruses, or bacteriophages (phages), that could be harnessed to combat multidrug-resistant enterococcal infections. Bacterial phage resistance represents a potential barrier to the implementation of phage therapy, emphasizing the importance of investigating the molecular mechanisms underlying the emergence of phage resistance. Using a cohort of 19 environmental lytic phages with tropism against E. faecalis, we found that these phages require the enterococcal polysaccharide antigen (Epa) for productive infection. Epa is a surface-exposed heteroglycan synthesized by enzymes encoded by both conserved and strain-specific genes. We discovered that exposure to phage selective pressure favors mutation in nonconserved epa genes both in culture and in a mouse model of intestinal colonization. Despite gaining phage resistance, epa mutant strains exhibited a loss of resistance to cell wall-targeting antibiotics. Finally, we show that an E. faecalisepa mutant strain is deficient in intestinal colonization, cannot expand its population upon antibiotic-driven intestinal dysbiosis, and fails to be efficiently transmitted to juvenile mice following birth. This study demonstrates that phage therapy could be used in combination with antibiotics to target enterococci within a dysbiotic microbiota. Enterococci that evade phage therapy by developing resistance may be less fit at colonizing the intestine and sensitized to vancomycin, preventing their overgrowth during antibiotic treatment.


  • Top Cited Papers
    Open Access

    Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia

    by Hana Hakim, Ronald Dallas, Joshua Wolf, Li Tang, Stacey Schultz-Cherry, Victoria Darling, Cydney Johnson, Erik A Karlsson, Ti-Cheng Chang, Sima Jeha, et al.

    Myelosuppression-related infections remain important causes of morbidity and mortality in children with acute lymphoblastic leukemia (ALL). By analyzing fecal samples collected at diagnosis and after each of the initial 3 phases of chemotherapy, we evaluated the role of gut microbiota in predicting infections in 199 children with newly diagnosed ALL. The bacterial 16S rRNA gene was analyzed by high-depth sequencing to determine the diversity and composition of the microbiome. After the induction and reinduction I phases of chemotherapy, microbial diversity decreased significantly relative to the prechemotherapy value. After chemotherapy, the relative abundance of certain bacterial taxa (eg, Bacteroidetes) decreased significantly, whereas that of other taxa (eg, Clostridiaceae and Streptococcaceae) increased. A baseline gut microbiome characterized by Proteobacteria predicted febrile neutropenia. Adjusting for the chemotherapy phase and ALL risk level, Enterococcaceae dominance (relative abundance ≥30%) predicted significantly greater risk of subsequent febrile neutropenia and diarrheal illness, whereas Streptococcaceae dominance predicted significantly greater risk of subsequent diarrheal illness. In children undergoing therapy for newly diagnosed ALL, the relative abundance of Proteobacteria before chemotherapy initiation predicts development of febrile neutropenia, and domination of the gut microbiota by Enterococcaceae or Streptococcaceae at any time during chemotherapy predicts infection in subsequent phases of chemotherapy. NCT00549848.


  • Astrovirus Biology and Pathogenesis

    by Valerie Cortez, Victoria A. Meliopoulos, Erik A. Karlsson, Virginia Hargest, Cydney Johnson, Stacey Schultz-Cherry

    Astroviruses are nonenveloped, positive-sense single-stranded RNA viruses that cause gastrointestinal illness. Although a leading cause of pediatric diarrhea, human astroviruses are among the least characterized enteric RNA viruses. However, by using in vitro methods and animal models to characterize virus-host interactions, researchers have discovered several important properties of astroviruses, including the ability of the astrovirus capsid to act as an enterotoxin, disrupting the gut epithelial barrier. Improved animal models are needed to study this phenomenon, along with the pathogenesis of astroviruses, particularly in those strains that can cause extraintestinal disease. Much like for other enteric viruses, the current dogma states that astroviruses infect in a species-specific manner; however, this assumption is being challenged by growing evidence that these viruses have potential to cross species barriers. This review summarizes these remarkable facets of astrovirus biology, highlighting critical steps toward increasing our understanding of this unique enteric pathogen.


  • Open Access

    Astrovirus Pathogenesis

    by Cydney Johnson, Virginia Hargest, Valerie Cortez, Victoria A. Meliopoulos, Stacey Schultz-Cherry

    Astroviruses are a major cause of diarrhea in the young, elderly, and the immunocompromised. Since the discovery of human astrovirus type 1 (HAstV-1) in 1975, the family Astroviridae has expanded to include two more human clades and numerous mammalian and avian-specific genotypes. Despite this, there is still little known about pathogenesis. The following review highlights the current knowledge of astrovirus pathogenesis, and outlines the critical steps needed to further astrovirus research, including the development of animal models of cell culture systems.